Federal Judge Approves $93 Million Settlement in Lipitor Antitrust Dispute

A New Jersey federal judge gave final approval on Wednesday to a $93 million settlement between a class of buyers of Lipitor and Pfizer. This resolution addresses the claims that Pfizer conspired with a drug manufacturer to delay the release of a cheaper generic version of Lipitor, thereby monopolizing the market. This settlement marks the culmination of a significant antitrust litigation battle. Further details of the proceedings and the implications of the settlement can be viewed here.